Search research articles
Contact Us
Filters
Showing results (91-100 of 99) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 99 results.
Cancer Letters
|
February 7, 2001
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro
I Noci, M Coronnello, P Borri, et al.
Journal of Endocrinological Investigation
|
September 23, 2019
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study
E M Presotto, G Rastrelli, I Desideri, et al.
British Journal of Cancer
|
August 22, 2002
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study
B Neri, G Cini, L Doni, et al.
The Pharmacogenomics Journal
|
October 22, 2014
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
E Cecchin, G Perrone, S Nobili, et al.
Bone Marrow Transplantation
|
November 2, 2004
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis
R Saccardi, A Tyndall, G Coghlan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2014
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
H Blons, J F Emile, K Le Malicot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 30, 2016
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients
J Taieb, R Balogoun, K Le Malicot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2014
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
E Bajetta, I Floriani, M Di Bartolomeo, et al.
JCO Precision Oncology
|
August 9, 2018
Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy
W L Allen, P D Dunne, S McDade, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 99) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 99 results.
Cancer Letters
|
February 7, 2001
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro
I Noci, M Coronnello, P Borri, et al.
Journal of Endocrinological Investigation
|
September 23, 2019
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study
E M Presotto, G Rastrelli, I Desideri, et al.
British Journal of Cancer
|
August 22, 2002
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study
B Neri, G Cini, L Doni, et al.
The Pharmacogenomics Journal
|
October 22, 2014
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
E Cecchin, G Perrone, S Nobili, et al.
Bone Marrow Transplantation
|
November 2, 2004
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis
R Saccardi, A Tyndall, G Coghlan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2014
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
H Blons, J F Emile, K Le Malicot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 30, 2016
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients
J Taieb, R Balogoun, K Le Malicot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2014
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
E Bajetta, I Floriani, M Di Bartolomeo, et al.
JCO Precision Oncology
|
August 9, 2018
Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy
W L Allen, P D Dunne, S McDade, et al.
Page
of 10